Pharmacyclics Xcytrin Is "Not Approvable" For Brain Metastases
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pharmacyclics' anti-cancer product Xcytrin (motexafin gadolinium) received a "not approvable" letter, closing the current chapter in a year-long fight to get the drug approved
You may also be interested in...
BrainStorm’s ALS Treatment NurOwn, Filed Over Protest, Will Get US FDA Panel Review
A November 2022 refuse-to-file letter cited clinical and statistical issues for the stem cell therapy, which failed its Phase III clinical efficacy endpoint. However, BrainStorm has consistently asserted that NurOwn demonstrated benefit in patients with less advanced disease at baseline, and it is encouraged by regulatory flexibility FDA recently has shown for the neurodegenerative disease.
NME Goal Dates Sparse In Late 2007: Third Year Of Low NME Count Likely
Only three NDAs for new molecular entities have user fee goal dates in the remainder of 2007, which implies a marked slow-down in the pace of NME actions after FDA’s busy October.
Genzyme Receives Complete Response, Warning Letters For Lumizyme
The hits just keep on coming for Genzyme. On a March 2 call with investors, the firm had to announce not just a "complete response" letter for its 2000-liter scale-up of Myozyme (which will be called Lumizyme for the larger production scale), but also that its Allston Landing manufacturing site had received a 483 report from FDA and a subsequent warning letter